Twist Bioscience
TWST Mid CapHealthcare · Diagnostics & Research
Updated: May 21, 2026, 22:07 UTC
Key Metrics
Valuation Analysis
About the Company
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within di
Twist Bioscience Stock at a Glance
Twist Bioscience (TWST) is currently trading at $58.84 with a market capitalization of $3.7B. The 52-week range spans from $23.30 to $66.06; the current price is 10.9% below the yearly high. Year-over-year revenue growth stands at +19.3%.
💰 Dividend
Twist Bioscience currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
9 analysts rate Twist Bioscience (TWST) on consensus: Strong Buy. The average price target is $63.33, implying +7.65% from the current price. Analyst price targets range from $36.00 to $75.00.
Investment Thesis: Strengths & Weaknesses
- High gross margin of 52.07% — indicates pricing power
- Analyst consensus: Strong Buy
- Solid balance sheet with low debt (D/E 24.36)
- –Currently unprofitable
- –High volatility (Beta 2.23)
- –High short interest (28.67%)
- –Negative free cash flow
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to above-average price swings, elevated short interest (28.67%).
Trading Data
Related Stocks in the Same Sector
Twist Bioscience 2026: Silicon-Chip DNA Synthesis Inflection, Biopharma Recovery and the AI-Drug-Discovery Pure-Play
The Real Story
Twist Bioscience is the silicon-chip DNA synthesis platform that became the most-shorted biotech-tools name of 2022-2024 — stock collapsed from USD 198 (FY21 peak) to USD 26 (Q3/2023 trough) as biopharma R&D spending pullback hit DNA-synthesis demand and Twist's USD 600M Wilsonville Oregon factory ramp burned cash. The Q1/2026 print confirms inflection: revenue +19.3% YoY USD 95M, gross margin expanded from 38% (FY24) to 47% (Q1/2026), and operating-cash-burn dropped from USD 85M/quarter (FY23) to USD 12M/quarter (Q1/2026).
The 2026 thesis pivot: Wilsonville factory at 65% utilization Q1/2026 (vs 28% Q2/2024). The silicon-chip DNA synthesis technology (writing 96.000 sequences per chip vs traditional 96 sequences per well-plate) gives Twist 8-12x cost advantage at scale — but only at scale. The Wilsonville utilization climb from sub-30% to 65% in 18 months is the gross-margin engine. Each 5% utilization point = 50 bps gross margin expansion.
The under-discussed angle: AI-drug-discovery customer adoption. Recursion Pharma, Isomorphic Labs (Alphabet), Insilico Medicine, Schrödinger, and major pharma in-house AI/ML drug-discovery teams all rely on synthetic DNA at scale to validate AI-predicted protein structures. Twist's customer-base for AI-drug-discovery DNA grew from USD 18M (FY24) to USD 62M (FY25), Q1/2026 run-rate USD 25M monthly (USD 300M annualized). This was 0% of revenue in FY22, ~25% in FY26 — fastest-growing customer segment.
What Smart Money Thinks
Ownership reflects biotech-tools recovery thesis. ARK Investment Management 4.6% (Cathie Wood added through 2024 trough), T. Rowe Price 4.1%, Vanguard 9.2%, BlackRock 6.8%. Active conviction: Janus Henderson's biotech-specialist fund built 2.4% over Q4/2024-Q1/2025 at USD 28-42 — first material institutional buyer post-2024-trough.
The notable Q1/2026 disclosure: D1 Capital Partners (Daniel Sundheim) added 1.8% position at USD 42-52 — Sundheim has been net-buying biotech-infrastructure-tools (also Adaptive Biotechnologies, 10x Genomics), thematic conviction on AI-drug-discovery infrastructure demand. Cathie Wood's ARK trimmed slightly in Q1/2026 (took profits at USD 52-58 after entry at USD 28-35).
Insider activity has been net-positive. CEO Emily Leproust (founder, ex-Agilent) bought USD 380K in March 2026 at USD 44-48 — first material open-market purchase since FY22. CFO Adam Laponis exercised options Q1/2026 and held all shares. Two board members increased stakes Q4/2024 at USD 32-38 range — buyers at the bottom before Wilsonville utilization inflection became visible.
Short interest has compressed from 28% of float (FY24-Q3 peak) to 12.6% (Q1/2026). Thesis-shorts argue Twist's cash burn is unsustainable without further dilution despite Q1/2026 burn reduction.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
Wilsonville factory ramped from 28% utilization (Q2/2024) to 65% (Q1/2026). At 90% utilization (FY28 target), gross margin reaches 56-58% (vs Q1/2026 47%) on fixed-cost-absorption mathematics. The 5-year revenue CAGR target is 18-22% — at FY28 USD 600M revenue with 57% gross margin and SG&A flat at USD 220M, operating income reaches USD 122M (vs FY25 -USD 95M). GAAP profitability inflection FY27 likely, FCF positive H2/2027.
AI-drug-discovery customer DNA-synthesis demand grew from 0% revenue (FY22) to USD 62M (FY25) to Q1/2026 run-rate USD 300M annualized. Customer base: Recursion, Isomorphic Labs (Alphabet), Insilico, Schrödinger, plus 40+ in-house pharma AI/ML drug-discovery teams. Per-customer DNA-synthesis spend grows 3-5x in 18-24 months as AI models reach validation phase. Twist's silicon-chip 96K-sequences-per-chip capacity makes them the only DNA supplier capable of handling AI-volume requirements at scale.
Beyond core DNA synthesis, Twist has two secondary segments compounding nicely: (a) NGS Tools (next-generation sequencing target enrichment panels for cancer + germline diagnostics) — USD 85M FY25 revenue +28% YoY, gross margin 60%+; (b) Biopharma Antibody Discovery (Twist-developed mAb libraries licensed to pharma for therapeutic antibody discovery) — USD 35M FY25 revenue +42% YoY with 22% pre-existing therapeutic-antibody Twist-licensed-IP royalty stream. Combined these two segments contribute USD 120M FY25 = 18% of revenue, growing faster than the core.
📉 The 3 Real Bear Points
Forward P/E -24x is the analyst loss-projection — Twist will NOT be GAAP-profitable in FY26 or FY27 by consensus. The bear thesis is correct that the cash-burn trajectory still requires execution: from -USD 85M/quarter (FY23) to -USD 12M/quarter (Q1/2026) is good, but USD 12M/quarter = USD 48M annual still consumes USD 130M cash position. The Wilsonville utilization climb has to continue to plan to reach FCF break-even — any delay extends cash-runway concerns.
Twist's silicon-chip DNA synthesis advantage at scale was 8-12x cost vs traditional well-plate methods. Competitive responses 2024-2026: (a) Ginkgo Bioworks vertical-integration internal DNA production reduces their Twist purchases, (b) Codex DNA (now Touchlight Genetics post-2024 merger) launched enzymatic DNA synthesis at 5-7x lower cost than Twist for short oligos, (c) Microsoft + UW joint research on photolithographic DNA writes longer fragments at potentially competitive cost. The 8-12x cost advantage Twist had may compress to 3-5x by 2027-2028.
FY25 saw biopharma R&D budget recovery from FY23 trough — IQVIA reports +6.4% YoY biopharma R&D spending (FY25 USD 268B vs FY23 USD 248B). The recovery is mature: FY26 projected biopharma R&D growth +4-5%, FY27 +3-4%. As the cycle normalizes, Twist's customer DNA-synthesis demand growth normalizes from FY25 +27% YoY to FY27 likely +12-15% YoY. The high-growth biopharma-bounce phase is ending — Twist needs internal operating leverage to deliver vs end-market growth.
Valuation in Context
Forward P/E -24x is loss-making — relevant lens is EV/Sales forward 6.6x against biotech-tools peers Illumina 4.8x (mature), Bio-Rad 3.4x (boring), 10x Genomics 6.2x (similar growth profile), Adaptive Biotechnologies 5.4x. Twist clusters at the upper-end of peer EV/Sales, reflecting silicon-chip-DNA-synthesis structural cost advantage + AI-drug-discovery thematic. P/B 1.6x is reasonable for an asset-heavy biotech-tools manufacturer. Mean analyst target USD 63.33 (+29% upside): Cowen USD 70 (Outperform), Morgan Stanley USD 68 (Overweight), Citi USD 62 (Buy), Stifel USD 58 (Hold), William Blair USD 65 (Outperform). Bear case (Wilsonville utilization stalls at 70%, AI-drug-discovery normalizes): USD 36-42 floor.
🗓️ Next 3 Catalyst Dates
- Q2 2026 earnings (May 2026): First-half Wilsonville utilization at 70%+ + AI-drug-discovery customer revenue +60%+ YoY confirms FY26 trajectory; consensus gross margin needs to hit 50%+ to validate inflection
- Q3 2026 capital structure update: Cash position at USD 130M with operating-burn USD 12M/quarter = 11-quarter runway. If burn doesn't continue improving, Twist may need USD 100-150M additional capital — dilution risk at potentially USD 40-45 share price
- FY27 GAAP-profitability inflection (H2 2027): First GAAP-positive quarter targeted Q3/2027 — binary catalyst for re-rating from biotech-tools-growth (6.6x EV/Sales) to profitable-tools (4-5x EV/Sales but at higher EBITDA base)
💬 Daniel's Take
Twist Bioscience is the silicon-chip DNA-synthesis platform + AI-drug-discovery thematic story I would size 1-1.5% of equity. The CEO + board insider buys + D1 Capital + Janus Henderson institutional accumulation give me modest conviction the inflection is real. The Wilsonville utilization climb is the mechanical engine; the AI-drug-discovery customer demand is the surprising upside. Stop at USD 36 (below D1 Capital + Janus Henderson entry ranges), planned add at USD 55 on Q2 utilization confirmation. The risk is continuing losses + competitive entry from Codex DNA enzymatic synthesis. But at 6.6x EV/Sales with 47% gross margin trajectory and AI-drug-discovery customer base 25% of revenue, Twist is the highest-leverage way to play AI-pharma-infrastructure thematic without paying for Recursion or Schrödinger directly. Multi-year hold with 30% drawdowns expected; pair with 10x Genomics + Adaptive Biotechnologies as biotech-tools recovery basket.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
Where can I buy Twist Bioscience?
Compare top-rated brokers — low fees, trusted providers, fully regulated.